...
首页> 外文期刊>The Journal of Clinical and Aesthetic Dermatology >Treatment of Melanoma Excision Wound With 50% Zinc Chloride Solution Astringent—Mohs Melanoma Surgery Without the Paste
【24h】

Treatment of Melanoma Excision Wound With 50% Zinc Chloride Solution Astringent—Mohs Melanoma Surgery Without the Paste

机译:用50%氯化锌溶液伤口的黑色素瘤切除伤口的治疗,莫氏黑色素瘤手术没有糊状物

获取原文
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Dr. Frederic Mohs believed that surgery can spread a melanoma; to prevent this, he applied an inactive black paste vehicle containing the active ingredient 50% zinc chloride solution to melanomas to kill and fix (i.e., preserve) tissue; this is termed fixed-tissue surgery . A statistically significant, 53-percent, five-year melanoma survival improvement in 103 consecutive cases was reported for fixed-tissue surgery compared to five-year survival for cases treated with conventional surgery ( p =0.003). Nine physicians, including the author, contributed to a melanoma registry of 179 cases between 1981 and 1991, and in 64 five-year determinate cases of thin melanomas (0.85mm), survival was improved by 60 percent with zinc chloride paste simply applied after excision to the open fresh-tissue wound compared to conventional surgery (95.7% five-year survival with zinc chloride applied to the excision wound vs. 88.9% five-year survival with conventional fresh-tissue excision only, hazard ratio 0.37). When applied to an open fresh excision wound in either a solution or paste form, zinc chloride penetrates instantly; the author has found both forms to be equally effective. In solution form, the application technique is simple and similar to the astringent 20% aluminum chloride solution applied with sterile gauze or Q-tip, but the inactive paste vehicle requires special dressings. Additionally, the inactive paste used by Mohs contains stibnite antimony; therefore, it cannot be formulated to USP standards and is not recognized by the FDA as a generally safe substance. However, zinc chloride is recognized by the FDA as a generally safe substance, and the 50% solution can be formulated by a compounding pharmacist to USP standards. 50% zinc chloride solution penetrates deeply and kills tissue and should not be used without previous biopsy confirmation of melanoma or melanoma in situ . The killing of tissue on the melanoma excision wound by the zinc chloride causes the wound to become deeper and wider, and therefore a smaller and thinner excision margin can be removed.
机译:背景:Frederic Mohs博士认为,手术可以传播黑色素瘤;为了防止这种情况,他将含有活性成分50%氯化锌溶液的非活性黑色粘贴载体施加到黑色素瘤中以杀死和固定(即保持)组织;这被称为固定组织手术。据报道,在常规手术治疗的病例的五年存活率上,报告了103例连续病例的统计学意义,五年的黑色素瘤生存改善。包括作者在内的九名医生促成了1981年至1991年的179例黑色素瘤注册表,在64例五年测定薄黑色素瘤(& 0.85mm)中,氯化锌糊剂简单地施加了60%与常规手术相比,切除开放的淡组织伤口(用氯化锌95.7%的五年存活,应用于切除伤口与88.9%的常规新鲜组织切除,危险比0.37)。当涂上溶液或糊状形式缠绕的开放式新鲜切除时,氯化锌立即穿透;作者发现这两种表格都同样有效。在溶液形式中,施用技术简单且与施用无菌纱布或Q尖的含量20%氯化铝溶液,但不活性的粘贴车辆需要特殊的敷料。另外,MOHS使用的非活性浆料含有Stibnite锑;因此,不能配制到USP标准,并不能被FDA识别为普遍安全的物质。然而,氯化锌被FDA识别为普遍的安全物质,并且50%溶液可以通过复合药剂师配制到USP标准。 50%氯化锌溶液深入渗透并杀死组织,不应在没有先前的黑素瘤或黑色素瘤的活检确认原位使用。通过氯化锌伤口造成黑色素瘤切除的组织导致伤口变得更深,更宽,因此可以去除较小和更薄的切除余量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号